Product Images Memantine Hydrochloride

This is a chart or graph showing the mean (standard error of mean) change in ADCS-ADL score from baseline for a clinical trial comparing placebo and memantine. The trial lasted for 28 weeks and had a clinical deadline for improvement.*

This appears to be a chart or graph with two lines representing the change from baseline in ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) for patients taking either placebo or memantine. The horizontal axis appears to be a scale of 0-10 and the vertical axis represents the percentage of patients. Without more context or information it is difficult to provide a more detailed description.*

Not available.*

The text is showing a graph with the cumulative percentage of patients along the y-axis, and SIB (Severe Impairment Battery) change from baseline on the x-axis. The graph compares two different treatments, Placebo, Donepezil, and Memantine/Donepezil. The graph shows that both treatments have a positive effect on SIB change from baseline and that the combination of Memantine/Donepezil has a higher cumulative percentage of patients with an SIB change from baseline compared to Placebo and Donepezil alone.*

This is a description of a medication with the National Drug Code 68180-229-07 containing 5mg of memantine hydrochloride USP. The tablets are film-coated and manufactured by Lupin Pharmaceuticals in Baltimore, Maryland. Dosage instructions and additional information about the medication can be found in the accompanying prescribing information. The medication should be stored in tight containers at temperatures between 15-30°C (59°t086°F). The manufacturer is Lupin Limited in Goa, India. The medication should be kept out of reach of children and dispensed with a patient information leaflet.*

This is a description of Memantine Hydrochloride Tablets USP, manufactured by Lupin Limited in Goa, India. The tablets are available in a pack of 100 and each film-coated tablet contains 5mg of memantine hydrochloride. The medication must be dispensed with a patient information leaflet separately provided to each patient. The prescription information and storage guidelines are also provided on the packaging. The lot number and a code number are printed on it, too.*

This is a description for a drug with the National Drug Code (NDC) 68180-230-07, containing memantine hydrochloride in tablets USP format, at a concentration of 10mg per tablet. The drug is only allowed to be dispensed with the patient information leaflet enclosed. It is recommended to be stored in a tight container, out of reach of children, and under controlled room temperature, ranging between 15-30°C (59-86°F). It is manufactured by Lupin Limited in Goa, India and distributed by Lupin Pharmaceuticals Inc. in Baltimore. Detailed information about dosage and usage is available in the accompanying prescribing information.*

This document is a description of a medication called Memantine Hydrochloride Tablets USP and Lupin. The tablets come in 100 pills and include Patient Information Leaflets. The dosage and usage of the medication are not clear in this fragment. The storage instructions indicate that the drug can be stored at temperatures ranging from 15° to 30°C. The manufacturer of the pills is Lupin Pharmaceuticals, and it was produced in Goa, India.*